Press Release

NeoGenomics, the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, and the Northwestern Medicine Developmental Therapeutics Institute Launch Collaborative Translational Research Program

NeoGenomics Reports 38% increase in Revenue to a Record $23.2 Million and Adjusted EBITDA of $2.6 Million for the Third Quarter of 2014

NeoGenomics is First to Offer Molecular Testing for Resistance to Bruton Tyrosin Kinase Inhibitors for Chronic Lymphocytic Leukemia

NeoGenomics Launches 315 Gene Next Generation Sequencing Test for Solid Tumor Discovery Profiling

NeoGenomics Appoints Robert J. Shovlin as Chief Operating Officer

NeoGenomics Schedules its Q3 2014 Earnings Release for October 30, 2014

NeoGenomics Announces Closing of Recent Equity Offering and Exercise in Full of Underwriters' Over-Allotment Option

NeoGenomics Announces Pricing of $32.2 Million Public Offering

Contact Us To Get Started!

Work with us – your premier oncology partner – to optimize cancer care for patients